Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: Cohort Norway

European Journal of Preventive Cardiology

Volumn 22, Issue 7, 2015, Pages 872-881

  Egeland, Grace M ^a,b   Igland, Jannicke ^b   Sulo, Gerhard ^b   Nygård, Ottar ^b,c   Ebbing, Marta ^a   Tell, Grethe S ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myocardial infarction; lipids

Indexed keywords

DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS ANTIBODY; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ADULT; AGE; ANTIBODY DETECTION; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HEALTH SURVEY; HIGH RISK POPULATION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NORWEGIAN (PEOPLE); PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HOSPITAL DISCHARGE; INCIDENCE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NORWAY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

ADULT; BIOMARKERS; CHOLESTEROL, HDL; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NORWAY; PATIENT DISCHARGE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 84930586154     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314535681     Document Type: Article

References (43)

1. Gotto AM. Triglyceride: the forgotten risk factor. Circulation. 1998 ; 97: 1027-1028
2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 ; 3: 213-219
3. Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med. 2002 ; 2: 325-333
4. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 ; 115: 450-458
5. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 ; 302: 1993-2000
6. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 ; 51: 1512-1524
7. Rashid S, Watanabe T, Sakaue T, et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003 ; 36: 421-429
8. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979 ; 60: 473-485
9. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, et al. Clinical relevance of postprandial lipaemia. Curr Med Chem. 2005 ; 12: 1931-1945
10. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 ; 298: 299-308
11. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 ; 298: 309-316
12. Lindman AS, Veierod MB, Tverdal A, et al. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur J Epidemiol. 2010 ; 25: 789-798
13. Stensvold I, Tverdal A, Urdal P, et al. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993 ; 307: 1318-1322
14. Austin MA. Triacylglycerol and coronary heart disease. Proc Nutr Soc. 1997 ; 56: 667-670
15. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004 ; 110: 2678-2686
16. Rubies-Prat J, Ordonez-Llanos J, Martin S, et al. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension. Clin Exp Hypertens. 2001 ; 23: 489-500
17. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001 ; 34: 583-588
18. Ohta T, Saku K, Takata K, et al. Fractional esterification rate of cholesterol in high density lipoprotein (HDL) can predict the particle size of low density lipoprotein and HDL in patients with coronary heart disease. Atherosclerosis. 1997 ; 135: 205-212
19. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003 ; 31: 1066-1069
20. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007 ; 18: 427-434
21. Jeppesen J, Hein HO, Suadicani P, et al. High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hypertension. 2000 ; 36: 226-232
22. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992 ; 70: 3H - 9H
23. Abdel-Maksoud MF, Eckel RH, Hamman RF, et al. Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men. J Clin Lipidol. 2012 ; 6: 374-381
24. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998 ; 97: 1029-1036
25. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol. 1992 ; 8: 99-103
26. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993 ; 328: 1220-1225
27. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009 ; 55: 35-41
28. Naess O, Sogaard AJ, Arnesen E, et al. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol. 2008 ; 37: 481-485
29. Rabanal KS, Lindman AS, Selmer RM, et al. Ethnic differences in risk factors and total risk of cardiovascular disease based on the Norwegian CONOR study. Eur J Prev Cardiol. 2013 ; 20: 1013-1021
30. Sulo G, Igland J, Nygård O, et al. Favourable trends in incidence of AMI Norway during 2001-2009 do not include younger adults: a CVDNOR project. Eur J Prev Cardiol. 2013 ;:
31. Sulo G IJ, Vollset SE, Nygård O, et al. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009. CVDNOR - a nationwide research project. Nor J Epidemiol. 23: 101-107
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106: 3143-3421
33. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Statistics in Medicine. 2010 ; 29: 1037-1057
34. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics in Medicine. 2011 ; 30: 11-21
35. Pencina MJ, D'Agostino RB, D'Agostino RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in Medicine. 2008 ; 27: 157-172
36. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011 ; 58: 457-463
37. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 ; 307: 1302-1309
38. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006 ; 332: 73-78
39. Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis. 2010 ; 20: 474-480
40. Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007 ; 167: 1068-1074
41. Preis SR, Pencina MJ, Mann DM, et al. Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart Study. Diabetes Care. 2013 ; 36: 1590-1596
42. Jeppesen J, Hein HO, Suadicani P, et al. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. Am Heart J. 2003 ; 145: 103-108
43. Sarwar N, Sandhu MS, Ricketts SL, et al. for the Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010 ; 375: 1634-1639